# ViGeneron

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vigeneron

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Website: www.vigeneron.com
- Latest round: Series A (Nov 28, 2019)
- Investors on record: 2

## About

ViGeneron GmbH is a biotechnology company focused on advancing gene therapies for treating ophthalmic diseases. The firm utilizes innovative AAV technology platforms to address significant medical needs in eye care.ViGeneron GmbH, founded in 2017 and headquartered in Munich, Germany, specializes in gene therapy solutions for ophthalmic conditions. The company was founded by Stylianos Michalakis, who has a background in the biotechnology sector. In November 2019, ViGeneron raised an undisclosed amount in Series A funding led by Sequoia Capital China and WuXi AppTec Group, marking its first funding round.ViGeneron GmbH specializes in developing advanced gene therapies aimed at treating ophthalmic diseases, particularly those with significant unmet medical needs. The company has established three proprietary adeno-associated virus (AAV) technology platforms: the vgAAV vector platform, the vgRNA REVeRT vector platform, and the transactivation platform. The vgAAV platform enhances transduction efficiency, allowing for less invasive intravitreal treatments, thereby broadening its applicability across various retinal cell types. The vgRNA REVeRT platform addresses the challenge of large gene mutations by utilizing a unique vector approach that facilitates mRNA trans-splicing, while the transactivation platform offers the capability to modulate the expression of multiple genes simultaneously. These innovative therapies target ophthalmic diseases such as inherited retinal disorders, with potential applications in other medical fields, including neuroscience and cardiovascular diseases. ViGeneron's products are being developed primarily for markets in Europe and North America, where ophthalmic healthcare needs are significant.ViGeneron GmbH operates on a model that integrates partnerships with leading biopharmaceutical companies to expedite the development and commercialization of its gene therapy solutions. Revenue generation is driven through strategic collaborations and partnerships, where the firm engages in B2B transactions, providing its proprietary gene therapy technologies to industry partners involved in drug development. This model includes upfront payments, milestone payments linked to the achievement of specific development goals, and royalty agreements based on future sales of products that utilize ViGeneron’s technology. Specific pricing structures and transaction details for these services and products are not publicly disclosed.ViGeneron GmbH plans to continue developing its innovative gene therapy solutions, aiming to launch new products targeting various ophthalmic conditions in the near future. The company is focused on expanding its market reach into additional regions across Europe and North America, with specific timelines yet to be disclosed. The funding raised in November 2019 will support these initiatives, allowing for enhanced research and development efforts as well as strategic partnerships to facilitate market entry.

## Funding rounds

- Series A, Nov 28, 2019 — Hong Shan, Wuxi AppTec Group

## Investors

- Hong Shan — Series A
- Wuxi AppTec Group — Series A